Molecular studies regarding colon cancer cell line (HCT116) treated by new ruthenium and palladium complexes

Ru(H2dtpa) (H2O) and Pd (DME)Cl2 were prepared, and their structures were confirmed by different structural tools. [Ru(H4dtpa) (cysteine)] Cl was separated as a model for the interaction of Ru (III) complex containing DTPA ligand with its corresponding most active amino acid and the geometrical parameters for the ternary complex and their constituent ligands are evaluated. Cytotoxicity was examined for both complexes against different cancer cell lines (HCT116, A549 and Mcf7). They were tested against a normal human lung cell line (W138). In addition, both complexes ensured cytocidal, not cytostatic effect. Several molecular tools were utilized in order to figure out the mechanism of action that two complexes followed to inhibit human colon cancer (HCT116) cell line. Gene expression analysis, cell cycle assay, genomic DNA analysis, and apoptosis were a molecular techniques that proved both Ru(H2dtpa) (H2O) and Pd (DME)Cl2 complexes were promising and effective chemotherapeutic agents against colon carcinoma in this current study. So, authors recommended more in vivo future studies should be done to make sure of complexes bioactivity and safety before they would be used commercially.